Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.340
-0.220 (-6.18%)
May 2, 2025, 4:00 PM EDT - Market closed
Lipocine Revenue
In the year 2024, Lipocine had annual revenue of $11.20M, down -492.80%. Lipocine had revenue of $3.49M in the quarter ending December 31, 2024, with 1,514.99% growth.
Revenue (ttm)
$11.20M
Revenue Growth
-492.80%
P/S Ratio
1.59
Revenue / Employee
$699,884
Employees
16
Market Cap
17.87M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
LPCN News
- 5 weeks ago - Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - PRNewsWire
- 7 weeks ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - PRNewsWire
- 7 weeks ago - Lipocine Announces FDA Labeling Changes for Testosterone Products - PRNewsWire
- 3 months ago - Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PRNewsWire
- 4 months ago - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PRNewsWire
- 5 months ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire
- 6 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PRNewsWire
- 6 months ago - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - PRNewsWire